on August 24, 2006
Published online before print August 24, 2006, doi: 10.1161/01.ATV.0000242905.41404.68
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 6, 2006
Accepted on August 2, 2006
PAI-1 and the Metabolic Syndrome. Links, Causes, and Consequences
Marie-Christine Alessi and Irène Juhan-Vague *
From the Laboratory of Hematology, INSERM UMR 626, Faculty of Medicine, Marseilles, France.
* To whom correspondence should be addressed. E-mail: ijuhan{at}ap-hm.fr.
Abstract--The link between plasminogen activator inhibitor (PAI)-1 and the metabolic syndrome with obesity was established many years ago. Increased PAI-1 level can be now considered a true component of the syndrome. The metabolic syndrome is associated with an increased risk of developing cardiovascular disease, and PAI-1 overexpression may participate in this process. The mechanisms of PAI-1 overexpression during obesity are complex, and it is conceivable that several inducers are involved at the same time at several sites of synthesis. Interestingly, recent in vitro and in vivo studies showed that besides its role in atherothrombosis, PAI-1 is also implicated in adipose tissue development and in the control of insulin signaling in adipocytes. These findings suggest PAI-1 inhibitors serve in the control of atherothrombosis and insulin resistance.
Key words: adipose tissue • atherothrombosis • metabolic syndrome • obesity • PAI-1
This article has been cited by other articles:
 |
|
 |
|
  R. Serrano, J. Barrenetxe, J. Orbe, J. A. Rodriguez, N. Gallardo, C. Martinez, A. Andres, and J. A. Paramo Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1563 - R1569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bortolotti, R. Kreis, C. Debard, B. Cariou, D. Faeh, M. Chetiveaux, M. Ith, P. Vermathen, N. Stefanoni, K.-A. Le, et al. High protein intake reduces intrahepatocellular lipid deposition in humans Am. J. Clinical Nutrition, October 1, 2009; 90(4): 1002 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M J Hill, S Kumar, and P G McTernan Adipokines and the clinical laboratory: what to measure, when and how? J. Clin. Pathol., March 1, 2009; 62(3): 206 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Bigert, M Alderling, M Svartengren, N Plato, U de Faire, and P Gustavsson Blood markers of inflammation and coagulation and exposure to airborne particles in employees in the Stockholm underground Occup. Environ. Med., October 1, 2008; 65(10): 655 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. de Larranaga, S. P. Wingeyer, M. Graffigna, S. Belli, K. Bendezu, S. Alvarez, O. Levalle, and H. Fainboim Plasma Plasminogen Activator Inhibitor-1 Levels and Nonalcoholic Fatty Liver in Individuals With Features of Metabolic Syndrome Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 319 - 324. [Abstract] [PDF]
|
|
|
|
 |
|
 B. A Brooks, S. V McLennan, S. M Twigg, and D. K Yue Detection and characterisation of microcirculatory abnormalities in the skin of diabetic patients with microvascular complications Diabetes and Vascular Disease Research, March 1, 2008; 5(1): 30 - 35. [Abstract] [PDF]
|
|
|
|
|
|
G. P. Van Guilder, G. L. Hoetzer, J. J. Greiner, B. L. Stauffer, and C. A. DeSouza Metabolic syndrome and endothelial fibrinolytic capacity in obese adults Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2008; 294(1): R39 - R44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.E. Morange, N. Saut, M.C. Alessi, J.S. Yudkin, M. Margaglione, G. Di Minno, A. Hamsten, S.E. Humphries, D.A. Tregouet, and I. Juhan-Vague Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2250 - 2257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ingelsson, M. J. Pencina, G. H. Tofler, E. J. Benjamin, K. J. Lanier, P. F. Jacques, C. S. Fox, J. B. Meigs, D. Levy, M. G. Larson, et al. Multimarker Approach to Evaluate the Incidence of the Metabolic Syndrome and Longitudinal Changes in Metabolic Risk Factors: The Framingham Offspring Study Circulation, August 28, 2007; 116(9): 984 - 992. [Abstract] [Full Text] [PDF]
|
|